pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. Scynexis appears in 1 tracked Cross-Sector story from February 27, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Scynexis
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Centers for Disease Control and Prevention, the most common co-covered peer. Scynexis appears in 1 tracked Cross-Sector story from February 27, 2026. The tracked stories average 2 original sources each.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Scynexis. Shared-story counts are live from our verified record — not editorial picks.
New York health authorities have issued a high-level alert regarding the accelerated spread of a deadly, drug-resistant fungal pathogen across healthcare facilities. The pathogen, identified as Candida auris, poses a severe threat to immunocompromised patients and highlights a critical gap in the current antifungal pharmaceutical pipeline.